Private Advisor Group LLC Acquires Shares of 13,199 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Private Advisor Group LLC acquired a new stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 13,199 shares of the biotechnology company’s stock, valued at approximately $166,000.

A number of other institutional investors have also recently bought and sold shares of the business. SG Americas Securities LLC lifted its holdings in shares of Rocket Pharmaceuticals by 796.2% during the 4th quarter. SG Americas Securities LLC now owns 54,921 shares of the biotechnology company’s stock worth $690,000 after acquiring an additional 48,793 shares during the period. Jennison Associates LLC lifted its holdings in shares of Rocket Pharmaceuticals by 72.6% during the 4th quarter. Jennison Associates LLC now owns 70,304 shares of the biotechnology company’s stock worth $884,000 after acquiring an additional 29,564 shares during the period. Mirador Capital Partners LP lifted its holdings in shares of Rocket Pharmaceuticals by 403.9% during the 4th quarter. Mirador Capital Partners LP now owns 84,529 shares of the biotechnology company’s stock worth $1,063,000 after acquiring an additional 67,755 shares during the period. First Turn Management LLC lifted its holdings in shares of Rocket Pharmaceuticals by 10.8% during the 3rd quarter. First Turn Management LLC now owns 621,306 shares of the biotechnology company’s stock worth $11,476,000 after acquiring an additional 60,317 shares during the period. Finally, Sovran Advisors LLC bought a new stake in shares of Rocket Pharmaceuticals during the 4th quarter worth approximately $1,895,000. Institutional investors own 98.39% of the company’s stock.

Rocket Pharmaceuticals Price Performance

RCKT stock opened at $8.77 on Friday. The company has a fifty day moving average price of $10.67 and a 200-day moving average price of $14.45. The company has a market capitalization of $799.45 million, a P/E ratio of -3.19 and a beta of 0.98. Rocket Pharmaceuticals, Inc. has a 52-week low of $8.25 and a 52-week high of $28.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.06. As a group, equities analysts expect that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on RCKT shares. Needham & Company LLC cut their price target on shares of Rocket Pharmaceuticals from $52.00 to $42.00 and set a “buy” rating for the company in a report on Friday, February 28th. Canaccord Genuity Group cut their target price on shares of Rocket Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. Wedbush initiated coverage on shares of Rocket Pharmaceuticals in a research report on Monday, December 30th. They issued an “outperform” rating and a $32.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 19th. Finally, The Goldman Sachs Group cut their target price on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $42.30.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.